Efficacy and Safety of Ozoralizumab versus Moxibustion for Rheumatoid Arthritis

Authors

Luthfiana Rofhani Susanti, Medical Program, Faculty of Medicine, Universitas Airlangga, Surabaya, IndonesiaFollow
Arifa Mustika, Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, IndonesiaFollow
Lita Diah Rahmawati, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, IndonesiaFollow
Citrawati Dyah Kencono Wungu, Institute of Tropical Disease, Universitas Airlangga, Surabaya, IndonesiaFollow

ORCID ID

Arifa Mustika: https://orcid.org/0000-0001-6461-5782; Citrawati Dyah Kencono Wungu: https://orcid.org/0000-0001-5180-957X

Abstract

Rheumatoid arthritis is a chronic inflammatory disease that symmetrically damages the synovial membrane, affecting approximately 13% of the global population. Systemic complications and substantial declines in quality of life may result from untreated rheumatoid arthritis. This study investigated the safety and efficacy of moxibustion and ozoralizumab in reducing disease activity scores in rheumatoid arthritis patients. Between July 2023 and February 2025, we conducted a thorough search on four online databases (PubMed, Cochrane, Scopus, and ProQuest) using keywords, reference searches, and other methods following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The obtained randomized controlled trials (RCTs) were assessed using the Cochrane Risk of Bias 2 (ROB2) tool. MetaInsight version 5.2.1 was utilized to perform the indirect network meta-analysis, using mean difference (MD) as the summary statistics. The measurement of the Disease Activity Score 28 (DAS28) indicated that ozoralizumab had a more significant effect on rheumatoid arthritis compared to placebo (MD=-1.88, 95% CI=-2.24-(-1.52)) and moxibustion (MD=-0.69, 95% CI=-1.07-0.31). Ozoralizumab demonstrated mild, moderate, and severe side effects, whereas moxibustion displayed modest side effects in comparison to placebo. In summary, both ozoralizumab and moxibustion reduced DAS28 in patients with rheumatoid arthritis, with ozoralizumab proving to be the more effective treatment. However, the adverse effects of ozoralizumab were more varied than those of moxibustion.

Keywords

Ozoralizumab, Moxibustion, Rheumatoid Arthritis, DAS28, Medicine

First Page

358

Last Page

371

DOI

https://doi.org/10.20473/fmi.v60i4.64949

Publication Date

11-12-2024

Recommended Citation

Susanti, Luthfiana Rofhani; Mustika, Arifa; Rahmawati, Lita Diah; and Kencono Wungu, Citrawati Dyah (2024) "Efficacy and Safety of Ozoralizumab versus Moxibustion for Rheumatoid Arthritis," Folia Medica Indonesiana: Vol. 60: No. 4, Article 10.
DOI: https://doi.org/10.20473/fmi.v60i4.64949
Available at: https://scholarly.unair.ac.id/fk-fmi/vol60/iss4/10